Biogen and FDA issue a drug warning

Biogen and the FDA reported yesterday that the multiple sclerosis drug, Avonex might cause severe liver damage, including liver failure in rare cases, particularly among patients who drink alcohol. Amy Ryan, a spokeswoman for Biogen stated that there have only been a handful of cases out of ~130,000 patients using Avonex. The 'minor update' is made to the drug warning label upgrading liver problems from "precaution" to a stronger "warning".

Both FDA and Biogen claim no connection between the Avonex warning and Tysabri withdrawal, but state the timing was coincidental. It looks like the cards are stacking up against Biogen and putative treatments for MS.

FDA warning

related New York Times article

No comments:

Blog Archive